Compare SHBI & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHBI | REPL |
|---|---|---|
| Founded | 1876 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.2M | 692.8M |
| IPO Year | 1997 | 2018 |
| Metric | SHBI | REPL |
|---|---|---|
| Price | $19.19 | $2.46 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 9 |
| Target Price | ★ $19.17 | $5.67 |
| AVG Volume (30 Days) | 228.2K | ★ 9.8M |
| Earning Date | 04-23-2026 | 05-21-2026 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | ★ 34.85 | 5.25 |
| EPS | ★ 1.78 | N/A |
| Revenue | ★ $20,853,000.00 | N/A |
| Revenue This Year | $8.97 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | $10.97 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.67 | $1.50 |
| 52 Week High | $20.68 | $13.24 |
| Indicator | SHBI | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 33.62 |
| Support Level | $18.88 | $1.50 |
| Resistance Level | $19.31 | $8.83 |
| Average True Range (ATR) | 0.50 | 0.45 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 21.00 | 18.35 |
Shore Bancshares Inc is a financial holding company based in the United States. Through its subsidiaries, it provides consumer and commercial banking products and services, as well as secondary mortgage lending, trust, wealth management, and financial planning services. The group caters to both business and individual clients, offering checking, savings, certificates of deposit, and overnight investment sweep accounts; commercial lending services, including secured and unsecured loans, working capital loans, lines of credit, etc; and safe deposit boxes, debit cards, telephone banking, and other financial products and services.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.